WO1996040617A1 - Method of making (s)-3-(aminomethyl)-5-methylhexanoic acid - Google Patents
Method of making (s)-3-(aminomethyl)-5-methylhexanoic acid Download PDFInfo
- Publication number
- WO1996040617A1 WO1996040617A1 PCT/US1996/006819 US9606819W WO9640617A1 WO 1996040617 A1 WO1996040617 A1 WO 1996040617A1 US 9606819 W US9606819 W US 9606819W WO 9640617 A1 WO9640617 A1 WO 9640617A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aminomethyl
- acid
- methylhexanoic acid
- water
- methylhexanoic
- Prior art date
Links
- 0 CC(C1)*C(*)C1C#N Chemical compound CC(C1)*C(*)C1C#N 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/30—Preparation of optical isomers
- C07C227/34—Preparation of optical isomers by separation of optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/04—Formation of amino groups in compounds containing carboxyl groups
- C07C227/10—Formation of amino groups in compounds containing carboxyl groups with simultaneously increasing the number of carbon atoms in the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/19—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/19—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton
- C07C255/22—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same saturated acyclic carbon skeleton containing cyano groups and at least two carboxyl groups bound to the carbon skeleton
Definitions
- This invention relates to a method of making ( ⁇ ) -3-(aminomethyl) -5-methylhexanoic acid and to a method of obtaining (S) -3- (aminomethyl) -5- methylhexanoic acid from ( ⁇ ) -3- (aminomethyl) -5- methylhexanoic acid.
- Isobutyl- GABA is related to the endogenous inhibitory neurotransmitter ⁇ -aminobutyric acid or GABA, which is involved in the regulation of brain neuronal activity. It is thought that convulsions can be controlled by controlling the metabolism of the neurotransmitter ⁇ -aminobutyric acid. When the concentration of GABA diminishes below a threshold level in the brain, convulsions result (Karlsson A., et al. , Biochem. Pharmacol ..
- seizure means excessive unsynchronized neuronal activity that disrupts normal function.
- GABA L-glutamic acid decarboxylase
- the compound ( ⁇ ) -3- (aminomethyl) -5-methylhexanoic acid, a GAD activator has the ability to suppress seizures while avoiding the undesirable side effect of ataxia.
- (S) -3- (aminomethyl) -5-methylhexanoic acid has been prepared by two synthetic routes. These routes each use reactions that require n-butyllithium, and both routes contain a step that must be carried out at low temperatures ( ⁇ -35°C) under carefully controlled conditions. These synthetic routes include the use of (4R, 5S) -4-methyl-5-phenyl-2-oxazolidinone as a chiral auxiliary to introduce the stereochemical configuration needed in the final product. See, for example, United States Serial No. 08/064,285, which is hereby incorporated by reference. Although these routes provide the target compound in high enantiomeric purity, they are difficult to conduct on large-scale and use expensive reagents which are difficult to handle.
- ( ⁇ ) -isobutyl GABA can be synthesized in accordance with Andruszkiewicz, et al. , S ⁇ nthesi s. 1989;953.
- the synthesis described therein uses potentially unstable nitro compounds, including nitromethane, and an intermediate containing a nitro functional group, which is reduced to an amine in a potentially exothermic and hazardous reaction.
- the synthesis also uses lithium bis(trimethylsilylamide) at -78°C.
- the present method does not use nitro compounds, require low temperatures, or require strongly basic conditions.
- the present invention provides an efficient synthesis of isobutyl-GABA and provides for the resolution of racemic isobutyl-GABA to obtain the S-stereoisomer of isobutyl-GABA that avoids the above- identified problems.
- the present invention provides the compounds
- the present invention provides a method of making ( ⁇ ) -3- (aminomethyl) -5-methylhexanoic acid which
- a preferred method of making ( ⁇ )-3-(aminomethyl) 5-methylhexanoic acid comprises condensing
- alkaline earth metal carboxylate salt and hydrogenating the alkali or alkaline earth metal carboxylate salt to form ( ⁇ ) -3- (aminomethyl) -5- methylhexanoic acid.
- the present invention also provides a method for obtaining (S) -3- (aminomethyl) -5-methylhexanoic acid from ( ⁇ ) -3- (aminomethyl) -5-methylhexanoic acid which comprises combining ( ⁇ ) -3- (aminomethyl) -5- methylhexanoic acid and (S)-mandelic acid in water, an alcohol or a mixture of water and an alcohol; allowing a precipitate to form; introducing the precipitate into a polar aprotic solvent or a mixture of polar aprotic solvent and water to form a slurry; and collecting the solid from the slurry.
- the present invention provides an efficient synthesis of racemic isobutyl-GABA and a method for obtaining (S) -isobutyl- GABA from racemic isobutyl-GABA.
- R- ⁇ and R 2 are the same or different and are hydrogen, C- ⁇ -Cg alkyl, aryl, benzyl or C3 ⁇ Cg cycloalkyl; and M is hydrogen, an alkali metal, or an alkaline earth metal.
- (aminomethyl) -5-methylhexanoic acid (VII or racemic 3- (aminomethyl) -5-methylhexanoic acid), the method comprising condensing isovaleraldehyde (I) with (II) to for (III); reacting (III) with a cyanide source to form (IV); decarboxylating (IV) to form (V) ; hydrolyzing (V) with an alkali metal or alkaline earth metal hydroxide to form (VI); and hydrogenating (VI) to form ( ⁇ ) -3- (aminomethyl) -5-methylhexanoic acid (VII).
- ( ⁇ ) -3- (aminomethyl) -5-methylhexanoic acid can be made by condensing isovaleraldehyde (I) with (II) to form (III); reacting (III) with a cyanide source to form (IV); hydrolyzing and decarboxylating (IV) to form (VI); and hydrogenating (VI) to form ( ⁇ )-3- (aminomethyl) -5-methylhexanoic acid (VII).
- Also provided by the present invention is a method for obtaining (S) -3- (aminomethyl) -5-methylhexanoic acid (IX) from ( ⁇ ) -3- (aminomethyl) -5-methylhexanoic acid (VII), the method comprising combining ( ⁇ )-3- (aminomethyl) -5-methylhexanoic acid and (S)-mandelic acid in water, an alcohol or a mixture of water and an alcohol; allowing a precipitate to form; introducing the precipitate into a polar aprotic solvent, or a polar aprotic solvent and water, to form a slurry; and collecting the solid from the slurry.
- isovaleraldehyde is condensed with wherein R and R 2 are the same or different and are hydrogen C ⁇ -Cg alkyl, aryl, benzyl, or C3 ⁇ C cycloalkyl.
- This type of reaction is known to those skilled in the art as a Knoevenagel Condensation, and the conditions under which a Knoevenagel Condensation can be carried out are well known to those skilled in the art.
- the condensation can be achieved using a catalytic amount of a base such as di-n-propylamine.
- Other suitable catalysts are known in the literature. See for example, Tietze L.F., and Beifuss U.
- catalysts include pyrrolidine, ⁇ -alanine, ammonium acetate, di-isoproplylamine, and di-n-propylamine. These basic catalysts can also be used in combination with an acid such as p-toluene sulfonic acid or acetic acid.
- a preferred catalyst system in the present method is di-n-propylamine and acetic acid.
- reaction is run in a refluxing hydrocarbon solvent including, but not limited to, toluene, hexane, heptane, methyl tert-butyl ether or cyclohexane, with the azeotropic removal of water.
- a preferred solvent is hexane.
- olefin regioisomers can also be formed in the reaction, but are converted to the desired product in a subsequent step in the reaction sequence.
- C- ⁇ -Cg alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl and hexyl.
- Representative examples of C ⁇ C cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
- Representative examples of aryl groups include phenyl and substituted phenyl, naphthyl, pridinyl, and the like. The aryl moiety may be substituted with one or more substituents, which can be the same or different. Examples of such groups include C- ⁇ -C alkyl, C- ⁇ -Cg alkoxy and halogen.
- R ⁇ and R 2 are ethyl.
- the isovaleraldehyde and are added to the solvent along with the catalyst, and refluxed with azeotropic removal of water. It is also contemplated that additional catalyst may be added when the rate of azeotropic water collection slows .
- the progress of the condensation reaction may be monitored by methods well known in the art. A preferred monitoring method is gas chromatography (GC) .
- a cyanide source in a polar protic solvent such as ethanol, methanol, n-propanol, isopropanol, a mixture of water and alcohols, or polar aprotic solvents such as dimethylsulfoxide (DMSO) or DMSO/water, and then treated with an acid.
- a polar protic solvent such as ethanol, methanol, n-propanol, isopropanol, a mixture of water and alcohols, or polar aprotic solvents such as dimethylsulfoxide (DMSO) or DMSO/water
- DMSO dimethylsulfoxide
- suitable cyanide sources include, but are not limited to, hydrogen cyanide, acetone cyanohydrin or an alkali metal or alkaline earth metal cyanide, such as sodium cyanide, potassium cyanide, or magnesium cyanide.
- the this step may be used
- Suitable acids are acetic acid, hydrochloric acid, hydrobromic acid, sulfuric acid, benzoic acid, mandelic acid, p-toluenesulfonic acid, and the like.
- suitable solvents include mixtures of water and a polar solvent such as ethanol or dimethylsulfoxide (DMSO) .
- suitable salts include alkali metal and alkaline earth metal halides such as sodium chloride and alkali metal and alkaline earth metal cyanides such as sodium cyanide, magnesium cyanide, and the like.
- the alkali or alkaline earth metal hydroxide can be any alkali or alkaline earth metal hydroxide known to those skilled in the art.
- suitable alkali metal hydroxides include sodium hydroxide, lithium hydroxide, and potassium hydroxide.
- suitable alkaline earth metal hydroxides include calcium hydroxide and magnesium hydroxide.
- the reaction is usually run in a suitable protic solvent such as water or a mixture of water and a polar protic solvent such as methanol, ethanol, or isopropanol.
- the carboxylate salt can be reduced to give the alkali or alkaline earth metal salt of ( ⁇ )-3- (aminomethyl) -5-methylhexanoic acid.
- the carboxylate salt can be protonated with mineral acids or carboxylic acids to give the carboxylic acid and then the nitrile group of the carboxylic acid can be reduced. Conversely, the nitrile group of the carboxylate salt can be reduced, and subsequently protonated to form the carboxylic acid.
- the salt can be treated with mineral acids or carboxylic acids to give ( ⁇ )-3-(aminomethyl) - 5-methylhexanoic acid. Those skilled in the art are familiar with the reduction of nitrile functional groups .
- One common method of reducing a nitrile uses a hydrogenation catalyst, such as sponge nickel, in the presence of hydrogen.
- Other catalysts include palladium, platiu , rhodium, cobalt, and nickel.
- the reaction is run in a solvent system such as a mixture of water and a polar protic solvent.
- the amino carboxylate formed after nitrile reduction can be obtained in the acid form by treating the amino carboxylate with an acid.
- the mineral acids such as hydrochloric acid can be used.
- Carboxylic acids, such as acetic acid can also be used.
- the acid is acetic acid
- MOAc a byproduct formed by the reaction
- M is an alkali metal ion (Na, K, and the like)
- OAc an acetate ion.
- the salt MOAc is more soluble in aqueous alcoholic solvents than inorganic salts such as sodium chloride, potassium chloride, and the like.
- isolation of the product is simplified, and the need for ion exchange treatment to remove excess salts is avoided.
- the cyano acid may also be reduced using a suitable hydrogenation catalyst, such as sponge nickel and hydrogen, in a polar solvent such as methanol, ethanol, or isopropanol in combination with ammonia or a mixture of ammonia and water.
- suitable hydrogenation catalysts include palladium, platium, rhodium, cobalt, and nickel.
- an alkali or alkaline earth metal hydroxide such as potassium hydroxide or sodium hydroxide in an alcohol solvent, which promotes decarboxylation.
- Racemic 3- (aminomethyl) -5-methylhexanoic acid can be resolved, i.e., the enantiomers separated, by selective crystallization with (S)-mandelic acid.
- Racemic 3- (aminomethyl) -5-methylhexanoic acid and (S)-mandelic acid can be combined in a solvent such as water or an alcohol or a mixture of water and an alcohol to form a salt.
- suitable alcohols include methanol, ethanol, n-propanol, isopropanol, n-butanol, tert-butanol, and the like.
- the S,S salt precipitates from the solution, and the diastereomer, the R,S salt, stays in solution.
- Diasteriomeric purity of the S,S salt can be enhanced by further crystallizations. Additional (S)-mandelic acid can be included in the recrystallizations to enhance diastereomeric enrichment. In general, an excess of mandelic acid is used. It is also noted that mandelic acid can be used in combination with another acid in accordance with the "Pope-Peachy" method known in the art.
- Removal of (S) -mandelic acid from the salt to give enriched (S) -3- (aminomethyl) -5-methylhexanoic acid can be done using a polar aprotic solvent such as dimethylsulfoxide or mixtures of dimethylsulfoxide and water or tetrahydrofuran and water, at temperatures typically in the range of about 0°C to about 100°C.
- Trituration to obtain the S-enantiomer has the advantage that it is operationally simple and more economical than traditional acid/base or ion exchange methods .
- (S) -3- (aminomethyl) -5-methyl- hexanoic acid can be obtained by combining ( ⁇ )-3- (aminomethyl) -5-methylhexanoic acid with (R) -mandelic acid to give the R,R salt which crystallizes out of the solution leaving the solution enriched in (S)-3- (aminomethyl) -5-methylhexanoic acid which can then be isolated from the solution by methods well known to those skilled in the art.
- the (R) -mandelic salt of (S) -3- (aminomethyl) -5- methylhexanoic acid can be isolated as an intermediate, treated with a polar aprotic solvent or mixture of water and a polar aprotic solvent to give the (S)-3- (aminomethyl) -5-methylhexanoic acid. It is also possible to obtain (S) -3- (amino methyl) -5-methylhexanoic acid from racemic isobutyl- GABA by standard methods of resolution known to those skilled in the art. It is noted that the isolated solids may be dried at each stage in the resolution or carried on to the next step as solvent-wet solids with comparable results . Also provided by the present invention are the novel compounds
- R- ⁇ and R 2 are the same or different and are hydrogen, C- ⁇ -Cg alkyl, aryl, benzyl or C ⁇ ⁇ c 6 cycloalkyl;
- M is hydrogen, an alkali metal, or an alkaline
- Isovaleraldehyde (361.6 kg, 4198.3 mol) was combined with diethyl malonate (640.8 kg, 4000.7 mol), hexane (1000 L) , di-n-propylamine (20.0 kg, 197.6 mol), and glacial acetic acid (24.0 kg, 399.7 mol) in a 4000 L vessel.
- the mixture was heated to reflux (jacket temperature set at 90°C) with continuous removal of water until the rate of water collection slowed significantly (69.4 kg water was collected versus 72.0 kg expected by theory).
- the mixture was heated to reflux (jacket temperature set at 90°C) with continuous removal of water for an additional 22.5 hours or until the reaction is judged complete by GC assay (>90% combined product and isomer) .
- the mixture was brought to ⁇ 40°C and was washed with water (2 x 800 L) .
- the organic layer was concentrated by atmospheric pressure distillation until most of the hexane was removed.
- the remaining oil was further concentrated by vacuum distillation at 40°C for 2-18 hours.
- the product was obtained as a colorless liquid (810.0 kg, 88.7% yield) and contained a mixture of olefin isomers (both of which are converted to the same product in the next synthetic step) .
- the major isomer is 2-carboxyethyl-5-methylhe ⁇ -2-enoic acid, ethyl ester; the minor isomer (typically 10-13% by GC) is believed to be 2-carboxyethyl-5-methylhex-3-enoic acid, ethyl ester.
- the batch was transferred to a hydrogenator containing sponge nickel (15.0 kg, 50% water wet), followed by a rinse of ethyl alcohol 2B (27 kg) .
- the mixture was treated with hydrogen at about 50 psi for about 19 hours (hydrogen uptake stopped) .
- the nickel was removed by filtration and the filter cake was rinsed with a mixture of 39 kg ethyl alcohol 2B and 111 L water.
- To the filtrate was added glacial acetic acid (22.8 kg, 380 mol) maintaining the batch temperature less than 40°C.
- the batch was heated to 70-75°C to dissolve the solids.
- the batch was slowly cooled to 0-5°C to crystallize the product.
- the solid was collected on a centrifuge and rinsed with 160 L isopropyl alcohol that was previously cooled to 0-5°C.
- the damp solid was dried in a vacuum tray drier under vacuum at 35-45°C (28 hours) to give 31.4 kg (75.1%) of racemic 3-aminomethyl-5-methylhexanoic acid.
- the product was characterized by HPLC and NMR.
- the water content for this product was 9.51% by weight (Karl Fischer) .
- the product may contain a variable amount of water ranging from nearly anhydrous up to about 10.2% (monohydrate) .
- the batch was concentrated by vacuum distillation to about 580 L volume. Water (100 L) was added and the distillation continued to a volume of about 510 L.
- the batch was transferred to an 800 L hydrogenator containing 44.8 kg sponge nickel (50% water wet), along with a mixture of 20 L water and 30 kg ethyl alcohol 2B as a rinse.
- the mixture was treated with hydrogen at about 50 psi for about 18-19 hours (hydrogen uptake stopped) .
- To the batch was added 58 kg ethyl alcohol 2B and the nickel was removed by filtration.
- the filter cake was rinsed with a mixture of 100 kg ethyl alcohol 2B and 270 L water.
- the filtrate was transferred to a 2000 L still containing 222 kg (3697 mol) glacial acetic acid at
- 50-60°C controlling the addition rate to control gas evolution and to maintain the temperature at 50-60°C.
- a rinse of 40 L water was added to the batch and the temperature increased to 70-75°C to dissolve the solids.
- the batch was slowly cooled to 0-5°C to crystallize the product.
- the solid was collected on a centrifuge and rinsed with 570 L isopropyl alcohol.
- the damp solid was dried in a vacuum tray drier under vacuum at 35-45°C (22 hours) to give 108.1 kg
- the product was characterized by HPLC and NMR.
- the product may contain variable amounts of water ranging from nearly anhydrous (1.68% by weight in this example) up to about 10.2% (monohydrate) .
- a solution of 3% v/v water in isopropyl alcohol was prepared by mixing water (9 kg) and isopropyl alcohol (291 L) in a 400 L reactor. This was repeated. The solvent was stored in plastic drums and used as necessary (described below) .
- the solid may optionally be dried at this stage or carried on as a solvent-wet solid) .
- the damp salt was charged to a 400 L still along with (S) -(+) -mandelic acid (5.8 kg, 38 mol) and 3% water/isopropyl alcohol (121 kg).
- the mixture was heated to dissolve the solids (about 65-80°C) , cooled, and seeded if necessary, with S,S-salt to crystallize the mixture of diastereomeric mandelate salts further enriched in the S,S-isomer.
- the solid was collected on a centrifuge and rinsed with 3% water/isopropyl alcohol (33.3 kg).
- the solid may optionally be dried at this stage or carried on as a solvent-wet solid (S/R isomer ratio: 99.5% S:0.5% R) .
- the dried S,S-salt typically has the following characteristics : Description: White to off-white solid; mp 133-134°C; 1 H NMR (D 2 0, 200 MHz): ⁇ 0.87-0.92 (m, 6H)
- the damp salt was transferred to a 400 L reactor with tetrahydrofuran (195 L) and water (10 kg). The mixture was warmed to 60-65°C, and cooled to 0-5°C.
- the crude (S) -isobutyl GABA solid was collected on a centrifuge and rinsed with a mixture of tetrahydrofuran (28 L)/water (1 kg). The solid may optionally be dried at this stage or carried on as a solvent-wet solid (S/R isomer ratio: 100% S: ⁇ 0.05% R isomer (not detected) ) .
- the damp solid was transferred to a 200 L still with isopropyl alcohol (113 L) and water (38 kg). The mixture was heated to dissolve the solids (about
- a solution of 3% v/v water in isopropyl alcohol was prepared by mixing water (5.7 kg) and isopropyl alcohol (184 L) in a 400 L reactor. The solvent was stored in plastic drums and used as necessary (described below) .
- a 2000 L reactor was charged with racemic 3-aminomethyl-5-methylhexanoic acid (117.6 kg, 673 mol) .
- a 2000 L still was charged with water (36 L), S- (+) -mandelic acid (153.0 kg, 1006 mol), and isopropyl alcohol (1170 L) .
- the mandelic acid mixture was heated to 55-65°C and the resulting solution was transferred to the reactor containing racemic 3-aminomethyl-5-methylhexanoic acid.
- the batch was heated to 50-65°C just long enough to dissolve the solids.
- the mixture was cooled to 40-45°C, seeded with S,S-salt (20 g), and further cooled to 20-25°C to crystallize the mixture of diastereomeric mandelate salts enriched in the S,S-isomer. After maintaining the temperature at 20-25°C for at least 12 hours, the solid was collected on a centrifuge and rinsed with 3% water/isopropanol solution (100 kg) prepared earlier. [Note: S/R isomer ratio: 92.5% S:7.5% R. The solid may optionally be dried at this stage or carried on as a solvent-wet solid.]
- the solvent-wet S,S-salt was charged to an 800 L reactor. An 800 L still was charged with water
- the mixture was cooled to 50-55°C. Seeding with S,S-salt at this temperature range is optional but is typically not needed to induce crystallization or further diastereomeric enrichment.
- the batch was further cooled to 0-5°C to crystallize the mixture of diastereomeric mandelate salts enriched in the S,S-isomer. After maintaining the temperature at 0-5°C for at least 12 hours, the solid was collected on a centrifuge and rinsed with 3% water/isopropanol solution (100 kg) prepared earlier.
- the solid may optionally be dried at this stage or carried on as a solvent-wet solid.
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP96914618A EP0830338B1 (en) | 1995-06-07 | 1996-05-13 | Method of making 3-(aminomethyl)-5-methylhexanoic acid |
PL96350438A PL185557B1 (en) | 1995-06-07 | 1996-05-13 | Method of separating (s)-3-(aminomethyl)-5-methylhexanic acid from (+)-3-(aminomethyl)-5-methylhexanic acid |
PL96350439A PL185560B1 (en) | 1995-06-07 | 1996-05-13 | Mandelic salt of 3-(aminomethyl)-5-methylhexanic acid |
SK1645-97A SK282865B6 (en) | 1995-06-07 | 1996-05-13 | Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid |
DE69617948T DE69617948T2 (en) | 1995-06-07 | 1996-05-13 | Process for the preparation of 3- (aminomethyl) -5-methylhexanoic acid |
JP50055997A JP3874306B2 (en) | 1995-06-07 | 1996-05-13 | Method for producing (S) -3- (aminomethyl) -5-methylhexanoic acid |
HU0500934A HU229957B1 (en) | 1995-06-07 | 1996-05-13 | Process for producing(s)-3-(aminomethyl)-5-methylhexanoic acid by resolving (+-)-3-(aminomethyl)-5-methylhexanoic acid |
EE9700320A EE04053B1 (en) | 1995-06-07 | 1996-05-13 | Method for the preparation of (S) -3- (aminomethyl) -5-methylhexanoic acid |
DK96914618T DK0830338T3 (en) | 1995-06-07 | 1996-05-13 | Process for the preparation of 3- (aminomethyl) -5-methylhexanoic acid |
AT96914618T ATE210628T1 (en) | 1995-06-07 | 1996-05-13 | METHOD FOR PRODUCING 3-(AMINOMETHYL)-5-METHYLHEXANIC ACID |
NZ308319A NZ308319A (en) | 1995-06-07 | 1996-05-13 | Method of making (s)-3-(aminomethyl)-5-methylhexanoic acid |
HU9802504A HU228194B1 (en) | 1995-06-07 | 1996-05-13 | Racemic 3-(aminomethyl)-5-methylhexanoic acid and it's intermediates and process for production thereof |
PL96323795A PL185425B1 (en) | 1995-06-07 | 1996-05-13 | Method of obtaining (s)-3-(aminomethyl)-5-methylhexanic acid |
SI9630390T SI0830338T1 (en) | 1995-06-07 | 1996-05-13 | Method of making 3-(aminomethyl)-5-methylhexanoic acid |
SK606-2002A SK283507B6 (en) | 1995-06-07 | 1996-05-13 | Method of making (+/-)-3-(aminomethyl)-5-methylhexanoic acid |
AU57921/96A AU700091C (en) | 1995-06-07 | 1996-05-13 | Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid |
CA002219150A CA2219150C (en) | 1995-06-07 | 1996-05-13 | Method of making (s)-3-(aminomethyl)-5-methylhexanoic acid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/474,874 US5637767A (en) | 1995-06-07 | 1995-06-07 | Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid |
US08/474,874 | 1995-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996040617A1 true WO1996040617A1 (en) | 1996-12-19 |
Family
ID=23885291
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/006819 WO1996040617A1 (en) | 1995-06-07 | 1996-05-13 | Method of making (s)-3-(aminomethyl)-5-methylhexanoic acid |
Country Status (18)
Country | Link |
---|---|
US (4) | US5637767A (en) |
EP (1) | EP0830338B1 (en) |
JP (1) | JP3874306B2 (en) |
AT (1) | ATE210628T1 (en) |
CA (1) | CA2219150C (en) |
CZ (2) | CZ291147B6 (en) |
DE (1) | DE69617948T2 (en) |
DK (1) | DK0830338T3 (en) |
EE (1) | EE04053B1 (en) |
ES (1) | ES2170231T3 (en) |
GE (1) | GEP19991870B (en) |
HU (2) | HU229957B1 (en) |
NZ (2) | NZ308319A (en) |
PL (3) | PL185425B1 (en) |
PT (1) | PT830338E (en) |
SI (1) | SI0830338T1 (en) |
SK (2) | SK283507B6 (en) |
WO (1) | WO1996040617A1 (en) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999008667A2 (en) * | 1997-08-19 | 1999-02-25 | Warner-Lambert Company | Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants |
WO2001055090A1 (en) * | 2000-01-27 | 2001-08-02 | Warner-Lambert Company | Asymmetric synthesis of pregabalin |
WO2006121557A1 (en) * | 2005-05-10 | 2006-11-16 | Teva Pharmaceutical Industries Ltd. | Pregabalin free of lactam and a process for preparation thereof |
WO2008062460A2 (en) * | 2006-10-06 | 2008-05-29 | Cadila Healthcare Limited | Crystalline forms of pregabalin |
US7417165B2 (en) | 2005-04-06 | 2008-08-26 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of pregabalin |
US7446220B2 (en) | 2005-09-19 | 2008-11-04 | Teva Pharmaceutical Industries Ltd. | Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid |
US7462737B2 (en) | 2005-05-10 | 2008-12-09 | Teva Pharmaceutical Industries Ltd. | Pregabalin free of isobutylglutaric acid and a process for preparation thereof |
US7462738B2 (en) | 2006-05-24 | 2008-12-09 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof |
US7488846B2 (en) | 2005-04-11 | 2009-02-10 | Teva Pharmaceuical Industries Ltd. | Pregabalin free of lactam and a process for preparation thereof |
WO2009122215A1 (en) * | 2008-04-04 | 2009-10-08 | Generics [Uk] Limited | Novel process |
WO2009125427A2 (en) * | 2008-02-18 | 2009-10-15 | Matrix Laboratories Limited | Process for preparing (s)-3-(aminomethyl)-5-methylhexanoic acid |
US7619112B2 (en) | 2005-05-10 | 2009-11-17 | Teva Pharmaceutical Industries Ltd. | Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid |
EP2170813A2 (en) * | 2007-06-25 | 2010-04-07 | Manne Satyanarayana Reddy | A novel process for the preparation of pregabalin |
US7763749B2 (en) | 2005-05-10 | 2010-07-27 | Teva Pharmaceutical Industries Ltd. | Method for the preparation of Pregabalin and salts thereof |
WO2011076915A1 (en) | 2009-12-24 | 2011-06-30 | Moehs Iberica S.L. | Novel method for the preparation of (s)-pregabalin field of the invention |
WO2011124934A1 (en) * | 2010-04-08 | 2011-10-13 | Richter Gedeon Nyrt. | Industrial process for the synthesis of (s)-(+)-pregabalin |
US8097754B2 (en) | 2007-03-22 | 2012-01-17 | Teva Pharmaceutical Industries Ltd. | Synthesis of (S)-(+)-3-(aminomethyl)-5-methyl hexanoic acid |
WO2011141923A3 (en) * | 2010-05-14 | 2012-01-19 | Lupin Limited | Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin |
EP2527319A1 (en) | 2011-05-24 | 2012-11-28 | Laboratorios Del. Dr. Esteve, S.A. | Crystalline forms of pregabalin and co-formers in the treatment of pain |
CN102102114B (en) * | 2004-06-21 | 2013-08-14 | 沃尼尔·朗伯有限责任公司 | Preparation of pregabalin and related compounds |
US8546112B2 (en) | 2008-05-21 | 2013-10-01 | Sandoz Ag | Process for the stereoselective enzymatic hydrolysis of 5-methyl-3-nitromethyl-hexanoic acid ester |
CN104086439A (en) * | 2014-06-30 | 2014-10-08 | 浙江华海药业股份有限公司 | Method for recovering pregabalin intermediate resolving agent (R)-(+)-alpha-phenylethylamine |
CN105061234A (en) * | 2015-08-18 | 2015-11-18 | 太仓运通生物化工有限公司 | Preparation method for pregabalin |
CN105085290A (en) * | 2015-08-18 | 2015-11-25 | 太仓运通生物化工有限公司 | Method for synthesizing pregabalin |
CN109942446A (en) * | 2019-04-17 | 2019-06-28 | 黄冈鲁班药业股份有限公司 | A kind of preparation method of Pregabalin |
WO2022119430A1 (en) | 2020-12-04 | 2022-06-09 | Laboratorios Silanes S.A. De C.V. | Stable coated solid pharmaceutical composition of an opioid analgesic and an anti-epileptic for pain |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5858736A (en) * | 1996-05-17 | 1999-01-12 | E. I. Du Pont De Nemours And Company | Preparation of lactams from aliphatic α,ω-dinitriles |
ATE241351T1 (en) | 1996-07-24 | 2003-06-15 | Warner Lambert Co | ISOBUTYLGABA AND ITS DERIVATIVES FOR PAIN TREATMENT |
RS20090257A (en) * | 1999-06-10 | 2010-03-02 | Warner-Lambert Company | Mono- and disubstituted 3-propyl gamma aminobutyric acids |
GB2368579A (en) * | 2000-10-31 | 2002-05-08 | Parke Davis & Co Ltd | Azole pharmaceutical agents |
US7169812B2 (en) * | 2003-07-01 | 2007-01-30 | Medtronic, Inc. | Process for producing injectable gabapentin compositions |
EP1543831A1 (en) * | 2003-12-18 | 2005-06-22 | Pfizer GmbH Arzneimittelwerk Gödecke | Pregabalin composition |
DK1727620T3 (en) * | 2004-03-12 | 2007-12-03 | Warner Lambert Co | C1 symmetric biphosphine ligands and their use in asymmetric synthesis of pregabiline |
UA82292C2 (en) * | 2004-04-14 | 2008-03-25 | Пфайзер Продактс Инк. | A method for stereoselective byconversion of aliphatic dinitriles into cyanocarboxylic acids (variants) |
CA2603215A1 (en) * | 2005-04-11 | 2006-10-19 | Teva Pharmaceutical Industries Ltd. | Process for making (s)-pregabalin |
NL2000281C2 (en) | 2005-11-02 | 2007-08-07 | Pfizer Prod Inc | Solid pharmaceutical compositions containing pregabalin. |
BRPI0702865A2 (en) * | 2006-04-24 | 2012-08-07 | Teva Pharma | processes for the preparation of 3-isobutylglutyric acid and (s) - pregabalin, from combinations of compositions with specific formulas for use in said preparation |
BRPI0702897A2 (en) | 2006-05-31 | 2011-03-15 | Teva Pharmaceutical Ind Ltda | process for preparing a pregabalin intermediate |
WO2007143152A2 (en) * | 2006-05-31 | 2007-12-13 | Teva Pharmaceutical Industries Ltd. | Preparation of (s)-pregabalin-nitrile |
CA2657544C (en) * | 2006-07-12 | 2013-05-28 | Generics [Uk] Limited | Process for preparing pregabalin |
WO2008138874A1 (en) * | 2007-05-09 | 2008-11-20 | Chemo Ibérica, S.A. | Process for preparing (s)-pregabalin by optical resolution of racemic pregabalin |
EP1992609A1 (en) * | 2007-05-14 | 2008-11-19 | Dipharma Francis S.r.l. | A process for the preparation of a (S)(+)-3-(aminomethyl)-5-methylhexanoic acid |
WO2009044409A2 (en) * | 2007-10-01 | 2009-04-09 | Natco Pharma Limited | Novel resolution process for pregabalin |
KR20090101462A (en) * | 2007-10-03 | 2009-09-28 | 테바 파마슈티컬 인더스트리즈 리미티드 | Pregabalin-4-eliminate, pregabalin-5-eliminate, their use as reference marker and standard, and method to produce pregabalin containing low levels thereof |
ITMI20072262A1 (en) | 2007-12-03 | 2009-06-04 | Dipharma Francis Srl | PROCEDURE FOR THE PREPARATION OF ACID (S) (+) - 3- (AMINOMETHYL) -5-METHYLESANOIC |
EP2225199A2 (en) * | 2007-12-18 | 2010-09-08 | Watson Pharma Private Limited | Improved process for the preparation of (s)-pregabalin |
CA2710152A1 (en) * | 2007-12-26 | 2009-07-02 | Generics (Uk) Limited | Processes to pregabalin |
US7879903B2 (en) | 2007-12-27 | 2011-02-01 | Toray Fine Chemicals Co., Ltd. | Optically active 3-aminopyrrolidine salt, process for production thereof, and method for optical resolution of 3-aminopyrrolidine |
DE112008003594B4 (en) | 2008-01-02 | 2018-04-26 | Zhejiang Jiuzhou Pharmaceutical Co., Ltd. | New separation process of S-3-aminomethyl-5-methylhexanoic acid |
EP2110372A1 (en) | 2008-04-16 | 2009-10-21 | Chemo Ibérica, S.A. | Intermediates for the preparation of Pregabalin and process for their preparation |
CN101585778B (en) * | 2008-05-19 | 2014-08-13 | 上海臣邦医药科技有限公司 | Lyrica preparation method |
WO2009147434A1 (en) * | 2008-06-03 | 2009-12-10 | Generics [Uk] Limited | A novel and efficient method for the synthesis of an amino acid |
KR20100107500A (en) * | 2008-06-23 | 2010-10-05 | 테바 파마슈티컬 인더스트리즈 리미티드 | Stereoselective enzymatic synthesis of (s) or (r)-iso-butyl-glutaric ester |
WO2010061403A2 (en) * | 2008-11-26 | 2010-06-03 | Ind-Swift Laboratories Limited | Process to prepare highly pure (s)-pregabalin |
WO2010070593A2 (en) | 2008-12-19 | 2010-06-24 | Pfizer Ireland Pharmaceuticals | Malonate esters |
IT1394292B1 (en) | 2009-05-07 | 2012-06-06 | Dipharma Francis Srl | PROCEDURE FOR THE SYNTHESIS OF PREGABALINA |
US8212072B2 (en) | 2010-08-13 | 2012-07-03 | Divi's Laboratories, Ltd. | Process for the preparation of pregabalin |
WO2012025861A1 (en) | 2010-08-23 | 2012-03-01 | Pfizer Manufacturing Ireland | Process for the preparation of ( s ) - 3 - cyano - 5 - methylhexanoic acid derivatives adn of pregabalin |
WO2012144551A1 (en) | 2011-04-20 | 2012-10-26 | 財団法人乙卯研究所 | Silicon-containing carboxylic acid derivative |
EP2910560B1 (en) | 2012-10-18 | 2017-09-06 | Kemphys Ltd. | Silicon-containing carboxylic acid derivative |
JP6482465B2 (en) | 2012-11-07 | 2019-03-13 | ハイカル リミテッド | Preparation method of pregabalin |
CN103980144B (en) * | 2014-05-16 | 2018-08-17 | 浙江华海药业股份有限公司 | A kind of using method of pregabalin intermediate mother liquor |
EP3154930B1 (en) | 2014-06-12 | 2018-04-18 | Siegfried Ltd. | Method for the preparation of beta-substituted gamma-amino carboxylic acids |
WO2016075082A1 (en) | 2014-11-10 | 2016-05-19 | Sandoz Ag | Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam |
CN104649919B (en) * | 2015-02-10 | 2021-02-12 | 浙江华海药业股份有限公司 | Preparation method of small-particle pregabalin |
CN107920987A (en) | 2015-05-26 | 2018-04-17 | 艾萨·欧蒂迪 | Control delays to discharge Pregabalin |
CN105175276A (en) * | 2015-07-25 | 2015-12-23 | 安徽东凯生物科技有限公司 | Synthetic method for optically pure(R)-3-carbamyl methyl-5-methyl caproic acid |
CN105348125A (en) * | 2015-11-26 | 2016-02-24 | 太仓运通生物化工有限公司 | Method for synthesizing Pregabalin by taking isovaleraldehyde as raw material |
CN111333529A (en) * | 2018-12-19 | 2020-06-26 | 北京万全德众医药生物技术有限公司 | Preparation method of pregabalin |
CN112939809A (en) * | 2020-12-30 | 2021-06-11 | 江苏恒沛药物科技有限公司 | Preparation method of 1-cyano-3-methyl diethyl butylmalonate |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0100019A1 (en) * | 1982-07-22 | 1984-02-08 | BASF Aktiengesellschaft | Process for the preparation of alpha-substituted beta-dicarbonyl-, beta-cyanocarbonyl- and beta-dicyano compounds |
EP0450577A1 (en) * | 1990-04-02 | 1991-10-09 | E.I. Du Pont De Nemours And Company | Nitrile-accelerated hydrocarboxylation |
WO1993023383A1 (en) * | 1992-05-20 | 1993-11-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2516307A (en) * | 1949-01-06 | 1950-07-25 | Gen Mills Inc | Vinyl resins plasticized with cyano esters |
US3110723A (en) * | 1959-08-18 | 1963-11-12 | Rohm & Haas | Process for preparing monochlorinated cyanoesters |
US3133954A (en) * | 1959-08-18 | 1964-05-19 | Rohm & Haas | Process for preparing chlorinated cyanoesters |
US3444161A (en) * | 1965-09-02 | 1969-05-13 | Shionogi Seiyaku Kk | Alkyl cyano aluminum compounds and process for introducing a cyano group into an alpha,beta unsaturated carbonyl compound |
DE1793347A1 (en) * | 1968-09-04 | 1972-02-03 | Dynamit Nobel Ag | Process for the preparation of substituted cyanobutyric acids |
JPS54100316A (en) * | 1978-01-25 | 1979-08-08 | Meiji Seika Kaisha Ltd | Preparation of derivative of aminobutyric acid |
US4428887A (en) * | 1982-07-14 | 1984-01-31 | Monsanto Company | Method of producing mono-substituted terminal diesters |
US4760089A (en) * | 1985-09-09 | 1988-07-26 | Smithkline Beckman Corporation | Irreversible dopamine-β-hydroxylase inhibitors |
US5132451A (en) * | 1989-08-25 | 1992-07-21 | Warner-Lambert Company | Process for cyclic amino acid anticonvulsant compounds |
US6197819B1 (en) * | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
US5366987A (en) * | 1991-08-22 | 1994-11-22 | Warner-Lambert Company | Isoxazolyl-substituted alkyl amide ACAT inhibitors |
-
1995
- 1995-06-07 US US08/474,874 patent/US5637767A/en not_active Expired - Lifetime
-
1996
- 1996-05-13 HU HU0500934A patent/HU229957B1/en unknown
- 1996-05-13 SK SK606-2002A patent/SK283507B6/en not_active IP Right Cessation
- 1996-05-13 PL PL96323795A patent/PL185425B1/en unknown
- 1996-05-13 CA CA002219150A patent/CA2219150C/en not_active Expired - Lifetime
- 1996-05-13 SI SI9630390T patent/SI0830338T1/en unknown
- 1996-05-13 PL PL96350439A patent/PL185560B1/en unknown
- 1996-05-13 GE GEAP19964087A patent/GEP19991870B/en unknown
- 1996-05-13 EP EP96914618A patent/EP0830338B1/en not_active Expired - Lifetime
- 1996-05-13 ES ES96914618T patent/ES2170231T3/en not_active Expired - Lifetime
- 1996-05-13 SK SK1645-97A patent/SK282865B6/en not_active IP Right Cessation
- 1996-05-13 WO PCT/US1996/006819 patent/WO1996040617A1/en active IP Right Grant
- 1996-05-13 CZ CZ19973846A patent/CZ291147B6/en not_active IP Right Cessation
- 1996-05-13 AT AT96914618T patent/ATE210628T1/en active
- 1996-05-13 CZ CZ20010732A patent/CZ296895B6/en not_active IP Right Cessation
- 1996-05-13 EE EE9700320A patent/EE04053B1/en unknown
- 1996-05-13 PL PL96350438A patent/PL185557B1/en unknown
- 1996-05-13 PT PT96914618T patent/PT830338E/en unknown
- 1996-05-13 HU HU9802504A patent/HU228194B1/en unknown
- 1996-05-13 NZ NZ308319A patent/NZ308319A/en not_active IP Right Cessation
- 1996-05-13 JP JP50055997A patent/JP3874306B2/en not_active Expired - Lifetime
- 1996-05-13 DE DE69617948T patent/DE69617948T2/en not_active Expired - Lifetime
- 1996-05-13 NZ NZ501628A patent/NZ501628A/en not_active IP Right Cessation
- 1996-05-13 DK DK96914618T patent/DK0830338T3/en active
-
1997
- 1997-02-06 US US08/796,159 patent/US5840956A/en not_active Expired - Lifetime
-
1998
- 1998-08-26 US US09/140,163 patent/US6046353A/en not_active Expired - Lifetime
-
1999
- 1999-10-05 US US09/412,258 patent/US20010016665A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0100019A1 (en) * | 1982-07-22 | 1984-02-08 | BASF Aktiengesellschaft | Process for the preparation of alpha-substituted beta-dicarbonyl-, beta-cyanocarbonyl- and beta-dicyano compounds |
EP0450577A1 (en) * | 1990-04-02 | 1991-10-09 | E.I. Du Pont De Nemours And Company | Nitrile-accelerated hydrocarboxylation |
WO1993023383A1 (en) * | 1992-05-20 | 1993-11-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
Non-Patent Citations (1)
Title |
---|
R. ANDRUSZKIEWICZ ET. AL.: "A Convenient Synthesis of 3-Alkyl-4-Aminobutanioc Acids", SYNTHESIS, no. 12, December 1989 (1989-12-01), NEW YORK, US, pages 953 - 5, XP002011378 * |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999008667A3 (en) * | 1997-08-19 | 1999-05-06 | Warner Lambert Co | Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants |
US6194459B1 (en) | 1997-08-19 | 2001-02-27 | Warner-Lambert Company | Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotors stimulants |
WO1999008667A2 (en) * | 1997-08-19 | 1999-02-25 | Warner-Lambert Company | Methods for treating physiological conditions associated with the use, or sequelae of use, of cocaine or other psychomotor stimulants |
WO2001055090A1 (en) * | 2000-01-27 | 2001-08-02 | Warner-Lambert Company | Asymmetric synthesis of pregabalin |
US6891059B2 (en) | 2000-01-27 | 2005-05-10 | Warner-Lambert Company | Asymmetric synthesis of pregabalin |
AP1438A (en) * | 2000-01-27 | 2005-05-23 | Warner Lambert Co | Asymmetric synthesis of pregabalin. |
HRP20020627B1 (en) * | 2000-01-27 | 2011-01-31 | Warner-Lambert Company | Asymmetric synthesis of pregabalin |
CN102102114B (en) * | 2004-06-21 | 2013-08-14 | 沃尼尔·朗伯有限责任公司 | Preparation of pregabalin and related compounds |
US7417165B2 (en) | 2005-04-06 | 2008-08-26 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of pregabalin |
US7488846B2 (en) | 2005-04-11 | 2009-02-10 | Teva Pharmaceuical Industries Ltd. | Pregabalin free of lactam and a process for preparation thereof |
WO2006121557A1 (en) * | 2005-05-10 | 2006-11-16 | Teva Pharmaceutical Industries Ltd. | Pregabalin free of lactam and a process for preparation thereof |
US7462737B2 (en) | 2005-05-10 | 2008-12-09 | Teva Pharmaceutical Industries Ltd. | Pregabalin free of isobutylglutaric acid and a process for preparation thereof |
US7763749B2 (en) | 2005-05-10 | 2010-07-27 | Teva Pharmaceutical Industries Ltd. | Method for the preparation of Pregabalin and salts thereof |
US7678938B2 (en) | 2005-05-10 | 2010-03-16 | Teva Pharmaceutical Industries Ltd. | Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid |
US7619112B2 (en) | 2005-05-10 | 2009-11-17 | Teva Pharmaceutical Industries Ltd. | Optical resolution of 3-carbamoylmethyl-5-methyl hexanoic acid |
US8212071B2 (en) | 2005-09-19 | 2012-07-03 | Teva Pharmaceutical Industries Ltd. | Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid |
US7563923B2 (en) | 2005-09-19 | 2009-07-21 | Teva Pharmaceutical Industries Ltd. | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin |
US7586005B2 (en) | 2005-09-19 | 2009-09-08 | Teva Pharmaceutical Industries Ltd. | Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid |
US7446220B2 (en) | 2005-09-19 | 2008-11-04 | Teva Pharmaceutical Industries Ltd. | Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid |
US7973196B2 (en) | 2005-09-19 | 2011-07-05 | Teva Pharmaceutical Industries Ltd. | Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid |
US7470812B2 (en) | 2005-09-19 | 2008-12-30 | Teva Pharmaceutical Industries Ltd. | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-Pregabalin |
US7687656B2 (en) | 2005-09-19 | 2010-03-30 | Teva Pharmaceutical Industries Ltd. | Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid |
US7960583B2 (en) | 2005-09-19 | 2011-06-14 | Teva Pharmaceutical Industries Ltd. | Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid |
US7923575B2 (en) | 2005-09-19 | 2011-04-12 | Teva Pharmaceutical Industries Limited | Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid |
US7465826B2 (en) | 2005-09-19 | 2008-12-16 | Teva Pharmaceutical Industries Ltd. | Chiral 3-carbamoylmethyl-5-methyl hexanoic acids, key intermediates for the synthesis of (S)-pregabalin |
US7851651B2 (en) | 2005-09-19 | 2010-12-14 | Teva Pharmaceutical Industries Ltd. | Asymmetric synthesis of (S)-(+)-3-(aminomethyl)-5-methylhexanoic acid |
US7462738B2 (en) | 2006-05-24 | 2008-12-09 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of R-(+)-3-(carbamoyl methyl)-5-methylhexanoic acid and salts thereof |
WO2008062460A2 (en) * | 2006-10-06 | 2008-05-29 | Cadila Healthcare Limited | Crystalline forms of pregabalin |
WO2008062460A3 (en) * | 2006-10-06 | 2009-01-15 | Cadila Healthcare Ltd | Crystalline forms of pregabalin |
US8097754B2 (en) | 2007-03-22 | 2012-01-17 | Teva Pharmaceutical Industries Ltd. | Synthesis of (S)-(+)-3-(aminomethyl)-5-methyl hexanoic acid |
EP2170813A4 (en) * | 2007-06-25 | 2012-05-16 | Reddy Manne Satyanarayana | A novel process for the preparation of pregabalin |
EP2170813A2 (en) * | 2007-06-25 | 2010-04-07 | Manne Satyanarayana Reddy | A novel process for the preparation of pregabalin |
WO2009125427A3 (en) * | 2008-02-18 | 2010-06-03 | Matrix Laboratories Limited | Process for preparing (s)-3-(aminomethyl)-5-methylhexanoic acid |
WO2009125427A2 (en) * | 2008-02-18 | 2009-10-15 | Matrix Laboratories Limited | Process for preparing (s)-3-(aminomethyl)-5-methylhexanoic acid |
CN102089273A (en) * | 2008-04-04 | 2011-06-08 | 基因里克斯(英国)有限公司 | Novel process |
WO2009122215A1 (en) * | 2008-04-04 | 2009-10-08 | Generics [Uk] Limited | Novel process |
US8546112B2 (en) | 2008-05-21 | 2013-10-01 | Sandoz Ag | Process for the stereoselective enzymatic hydrolysis of 5-methyl-3-nitromethyl-hexanoic acid ester |
WO2011076915A1 (en) | 2009-12-24 | 2011-06-30 | Moehs Iberica S.L. | Novel method for the preparation of (s)-pregabalin field of the invention |
WO2011124934A1 (en) * | 2010-04-08 | 2011-10-13 | Richter Gedeon Nyrt. | Industrial process for the synthesis of (s)-(+)-pregabalin |
EA023313B1 (en) * | 2010-04-08 | 2016-05-31 | Рихтер Гедеон Нирт. | Industrial process for the synthesis of (s)-(+)-pregabalin |
WO2011141923A3 (en) * | 2010-05-14 | 2012-01-19 | Lupin Limited | Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin |
EP2527319A1 (en) | 2011-05-24 | 2012-11-28 | Laboratorios Del. Dr. Esteve, S.A. | Crystalline forms of pregabalin and co-formers in the treatment of pain |
CN104086439A (en) * | 2014-06-30 | 2014-10-08 | 浙江华海药业股份有限公司 | Method for recovering pregabalin intermediate resolving agent (R)-(+)-alpha-phenylethylamine |
CN104086439B (en) * | 2014-06-30 | 2018-11-16 | 浙江华海药业股份有限公司 | A kind of recovery method of pregabalin intermediate resolving agent (R)-(+)-α-phenylethylamine |
CN105061234A (en) * | 2015-08-18 | 2015-11-18 | 太仓运通生物化工有限公司 | Preparation method for pregabalin |
CN105085290A (en) * | 2015-08-18 | 2015-11-25 | 太仓运通生物化工有限公司 | Method for synthesizing pregabalin |
CN109942446A (en) * | 2019-04-17 | 2019-06-28 | 黄冈鲁班药业股份有限公司 | A kind of preparation method of Pregabalin |
CN109942446B (en) * | 2019-04-17 | 2021-09-07 | 黄冈鲁班药业股份有限公司 | Preparation method of pregabalin |
WO2022119430A1 (en) | 2020-12-04 | 2022-06-09 | Laboratorios Silanes S.A. De C.V. | Stable coated solid pharmaceutical composition of an opioid analgesic and an anti-epileptic for pain |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0830338B1 (en) | Method of making 3-(aminomethyl)-5-methylhexanoic acid | |
EP0828704B1 (en) | Methods of making (s)-3-(aminomethyl)-5-methylhexanoic acid | |
WO2008009897A1 (en) | Process for preparing pregabalin and its opposite enantiomer | |
EP2017273A1 (en) | Process for the enantioselective preparation of pregabalin | |
AU700091C (en) | Method of making (S)-3-(aminomethyl)-5-methylhexanoic acid | |
MXPA97008652A (en) | Method for making acid (s) -3- (aminomethyl) -5-methylhexane | |
CA2219278C (en) | Methods of making (s)-3-(aminomethyl)-5-methylhexanoic acid | |
EP0837843B1 (en) | Method for preparing enantiomeric forms of amino alkylaminophenyl propanoic acid | |
WO2009127560A1 (en) | Intermediates for the preparation of pregabalin and process for their preparation | |
MXPA97008338A (en) | Methods to make acid (s) -3- (aminomethyl) -5-methylhexane |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CZ EE HU JP LT LV MX NZ PL RO SG SI SK AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2219150 Country of ref document: CA Kind code of ref document: A Ref document number: 2219150 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 308319 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Country of ref document: MX Ref document number: PA/a/1997/008652 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996914618 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV1997-3846 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 164597 Country of ref document: SK |
|
ENP | Entry into the national phase |
Ref document number: 1997 500559 Country of ref document: JP Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: PV1997-3846 Country of ref document: CZ Ref document number: PV2001-732 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1996914618 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2001-732 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996914618 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6062002 Country of ref document: SK |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1997-3846 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: PV2001-732 Country of ref document: CZ |